Profile
Sector:
HealthcareCountry:
United StatesIPO:
28 September 2000Website:
http://www.durect.comNext earnings report:
27 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 19 Nov 2024 21:05:32 GMTDividend
Analysts recommendations
Institutional Ownership
DRRX Latest News
Durect (DRRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.40 per share a year ago.
CUPERTINO, Calif. , Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024.
- Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of larsucosterol reduced 90-day mortality in U.S. patients by 57% and 58%, respectively, compared with placebo CUPERTINO, Calif. , Sept. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today provided details on the design of its upcoming registrational Phase 3 trial which will evaluate larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH).
CUPERTINO, Calif. , Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C.
Durect (DRRX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago.
- FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design - Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 - Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif.
CUPERTINO, Calif. , Aug. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August 13, 2024.
Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year.
DURECT Corporation's Q1 2024 Earnings Conference Call is scheduled for May 13, 2024 at 4:30 PM ET, with CFO Timothy M. Papp and James E. participating.
Durect (DRRX) reported a quarterly loss of $0.25 per share, which was slightly higher than the Zacks Consensus Estimate of a loss of $0.21. This is an improvement from the loss of $0.52 per share in the same quarter last year.
What type of business is DURECT?
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
What sector is DURECT in?
DURECT is in the Healthcare sector
What industry is DURECT in?
DURECT is in the Drug Manufacturers - Specialty & Generic industry
What country is DURECT from?
DURECT is headquartered in United States
When did DURECT go public?
DURECT initial public offering (IPO) was on 28 September 2000
What is DURECT website?
https://www.durect.com
Is DURECT in the S&P 500?
No, DURECT is not included in the S&P 500 index
Is DURECT in the NASDAQ 100?
No, DURECT is not included in the NASDAQ 100 index
Is DURECT in the Dow Jones?
No, DURECT is not included in the Dow Jones index
When was DURECT the previous earnings report?
No data
When does DURECT earnings report?
The next expected earnings date for DURECT is 27 March 2025